Scottish Universities Spearhead £1.75 Million Drive to Transform Bowel Cancer Prevention

Researchers from the University of Glasgow and Queen's University Belfast are at the forefront of a groundbreaking £1.75 million, five-year UK-wide programme funded by Cancer Research UK and the Bowelbabe Fund. This initiative promises to revolutionise how clinicians predict and prevent bowel cancer by delving deep into the progression of precancerous polyps. Led by Professor Joanne Edwards and Dr Stephen McSorley from Glasgow's School of Cancer Sciences, alongside Dr Philip Dunne from Queen's Belfast's Patrick G. Johnston Centre for Cancer Research, the study addresses a critical gap in current bowel cancer screening practices.

Bowel cancer, also known as colorectal cancer, remains the fourth most common cancer in the UK, with over 40,000 new diagnoses annually. In Scotland alone, around 4,000 cases are reported each year, underscoring the urgency of enhanced prevention strategies. The national Bowel Cancer Screening Programme (BCSP), which invites individuals aged 50 to 74 for faecal immunochemical testing (FIT) every two years, has been instrumental in early detection. However, while polyps—small growths in the bowel lining—are routinely removed during follow-up colonoscopies, distinguishing those likely to recur or turn cancerous remains challenging.

The Critical Role of Polyps in Bowel Cancer Development

Most bowel cancers evolve slowly from benign polyps over many years. The BCSP effectively identifies these through FIT-positive results leading to colonoscopy, where high-risk polyps are excised. Yet, surveillance post-removal poses dilemmas: not all patients require repeated invasive procedures, but missing high-risk cases can be fatal. Current assessments rely primarily on polyp size, number, and histology—methods proven insufficiently predictive.

This new programme will analyse thousands of polyp samples from screening participants using cutting-edge molecular technologies, pathology, and data analytics. By elucidating why some polyps progress while others regress, researchers aim to craft personalised risk profiles, optimising surveillance and sparing low-risk patients unnecessary colonoscopies.

University of Glasgow's Leadership in Translational Cancer Research

The University of Glasgow's School of Cancer Sciences stands as a powerhouse in oncology, with its research generating over £500 million in economic impact annually for the UK economy. Professor Joanne Edwards, Professor of Translational Cancer Pathology, brings over 20 years of expertise in cancer biomarkers, particularly in colorectal and breast cancers, boasting an H-index of 74. Her lab focuses on microenvironmental factors influencing tumour progression, making her ideal for leading polyp molecular profiling.

Dr Stephen McSorley, a Clinical Lecturer in General Surgery and Senior Clinical Research Fellow, completed his PhD on colorectal cancer surgery at Glasgow. His clinical insights into surgical outcomes and surveillance complement the basic science, bridging lab discoveries to patient care. Glasgow's prior INCISE project—a £3.37 million Innovate UK-funded effort using AI for polyp risk stratification—lays foundational work, demonstrating the university's prowess in digital pathology and precision medicine.

Queen's University Belfast: Expertise in Colorectal Cancer Progression

At Queen's University Belfast, the Patrick G. Johnston Centre for Cancer Research, named after its pioneering late director, hosts over 300 researchers tackling cancer from bench to bedside. Dr Philip Dunne, Reader in Molecular Pathology, specialises in phenotypic plasticity—the cancer cells' ability to adapt and resist treatments—in colorectal cancer. His work on disease progression mechanisms aligns perfectly with understanding polyp-to-cancer transitions.

Queen's involvement underscores Northern Ireland's growing role in UK cancer research, with the centre's interdisciplinary approach fostering innovations in personalised medicine. Collaborations like this highlight how devolved nations' universities drive national health advances.

Photo by 𝕡𝕒𝕨𝕤 𝕒𝕟𝕕 𝕡𝕣𝕚𝕟𝕥𝕤 on Unsplash

Innovative Methodology: From Polyps to Predictive Models

The programme's core involves biobanking thousands of polyps from NHS Scotland and Public Health Agency Northern Ireland cohorts. Advanced techniques—next-generation sequencing, spatial transcriptomics, and multi-omics—will map genetic, epigenetic, and microenvironmental changes. Professor Trevor Graham from the Institute of Cancer Research (ICR) London contributes expertise in cancer evolution, modelling clonal dynamics within polyps.

Integrated datasets will train machine learning algorithms for risk scores, potentially integrating with prior AI tools like those from Glasgow's INCISE project. This molecular precision surpasses traditional histology, promising tailored surveillance intervals.University of Glasgow's programme announcement details the multi-omics approach.

Overcoming Surveillance Challenges in the NHS

The BCSP has reduced bowel cancer mortality by detecting early lesions, yet post-polypectomy surveillance strains endoscopy capacity. Up to 25% of screening colonoscopies reveal polyps requiring follow-up, but interval cancers occur due to missed or aggressive lesions. Deprivation and ethnicity influence uptake and outcomes, with lower participation in deprived Scottish areas.

This study could halve unnecessary procedures, easing NHS waiting lists—currently over 500,000 for endoscopy—while prioritising high-risk cases. For universities, it exemplifies translational research's real-world impact.

Funding Legacy: Bowelbabe Fund and CRUK's University Investments

Cancer Research UK, the world's largest cancer charity, invests heavily in university-led prevention, with recent £5.5 million for bowel cancer personalisation. The Bowelbabe Fund, honouring Dame Deborah James, channels public donations into early detection. Such funding sustains PhD studentships and facilities at Glasgow and Queen's, nurturing next-gen researchers.

These grants highlight universities' pivotal role in CRUK's portfolio, generating societal returns like Glasgow's £500 million economic boost from cancer sciences.

Expected Impacts: Personalised Prevention and Global Resources

By 2031, outcomes could include validated biomarkers for risk-stratified surveillance guidelines, integrated into BCSP. Low-risk patients gain reassurance without repeat scopes; high-risk ones receive timely intervention. The biobank becomes a global asset, spurring international collaborations.

For UK higher education, it bolsters reputations—Glasgow ranks top in clinical research, Queen's excels in molecular oncology—driving PhD recruitment and grants. Quotes from leaders emphasise patient benefits: “This will help identify who needs more tests,” says Prof Edwards.

Photo by Vishnu Prasad on Unsplash

Career Opportunities in UK Cancer Research Universities

Such high-profile projects create demand for postdocs, clinical fellows, and data scientists at Glasgow and Queen's. Glasgow's Impact Lab translates findings commercially; Queen's ECMC runs early-phase trials. With bowel cancer's rising early-onset cases, research roles abound.

• PhD in colorectal -omics at Glasgow Precision Medicine DTP.
• Postdoc in pathology at Queen's Johnston Centre.
• Bioinformatics for polyp AI models.

These unis offer competitive salaries, with professors earning £100k+, fostering interdisciplinary careers.CRUK's bowel cancer trials hub lists opportunities.

Future Outlook: Universities Shaping UK Cancer Prevention

This programme exemplifies devolved excellence: Scottish and Northern Irish unis leading national efforts. Amid NHS pressures and rising incidences, university research is key to sustainable prevention. As Prof Edwards notes, better prediction means “reducing burden without compromising care.” Expect spin-outs, guidelines updates, and trained researchers advancing global oncology.

UK higher education's cancer ecosystem—bolstered by CRUK—positions Glasgow and Queen's as hubs for innovation, promising lives saved through precision prevention.